Core Insights - The launch of "Minsheng Lesuke," a smoking cessation drug by Minsheng Health, aims to provide a scientific and standardized solution for smokers in China, with a comprehensive sales strategy covering both online and offline channels [1][2] - The global smoking cessation market is projected to reach nearly 1 trillion by 2029, with a CAGR exceeding 19% from 2023 to 2029, indicating a significant growth opportunity in a market with limited supply and high demand [1] - The company positions "Minsheng Lesuke" as a strategic flagship product, focusing on scientific and user-friendly design to enhance treatment adherence, supported by a digital companion service to improve user success rates in quitting smoking [2] Industry Overview - The smoking cessation drug market is characterized by a blue ocean opportunity, with only four companies currently holding generic drug approvals in China following the withdrawal of Pfizer's original drug [1] - The company plans to leverage partnerships with domestic smoking cessation academic authorities and actively participate in setting industry standards to enhance its market presence [2] - Revenue projections for the company indicate a steady growth trajectory, with expected revenues of 792 million, 985 million, and 1.273 billion from 2025 to 2027, reflecting year-on-year growth rates of 24%, 24%, and 29% respectively [2]

Core Viewpoint - Minsheng Health announced on November 17 that its vitamin and mineral segment is expected to maintain steady growth due to continuous new product launches in both online and offline channels, as well as deepening offline channel engagement and expanding online channel reach [1] Group 1 - The company will continue to launch new products in both online and offline channels [1] - The company aims to expand product coverage through deepening offline channels and expanding online channels [1]

Company Overview - The company is Hangzhou Minsheng Health Pharmaceutical Co., Ltd., with the stock code 301507 and the abbreviation Minsheng Health [1] - The company focuses on four main product lines: liver disease, chronic diseases, ophthalmology and dermatology, and hematological oncology [1] Business Growth - The vitamin and mineral segment is expected to maintain steady growth due to the introduction of new products through both online and offline channels [1] - The company is expanding its product coverage by deepening offline channels and expanding online channels [1] New Product Launch - The new smoking cessation drug, Minsheng Lesuke (Varenicline Tartrate), is currently in the initial launch phase, with pre-sales on platforms like JD Health and Alibaba Health [2] - The drug is recommended as a first-line treatment by WHO and clinical guidelines in China and the US [2] Product Features - Minsheng Lesuke features a warm color packaging design to convey a positive message and enhance user recognition [2] - The product uses a dual aluminum high barrier packaging to ensure stability and ease of use, catering to the needs of elderly patients with a small dosage specification of 0.5mg [2] - A unique scientific smoking cessation app is provided to support users throughout their quitting journey [2] Investor Participation - The investor relations activity included participation from various financial institutions, including Dongwu Securities, Xinda Securities, and Huaxia Fund, among others [3][4]